ARCA biopharma to Present at the Growth Capital Expo 2014
April 22 2014 - 09:00AM
Business Wire
ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company
developing genetically-targeted therapies for cardiovascular
diseases, today announced that its Chief Financial Officer, Patrick
Wheeler, will present at the Growth Capital Expo 2014, taking place
April 29 – May 1, 2014. ARCA’s presentation will take place
Wednesday, April 30, 2014 at 10:30am PT. The Company’s presentation
will be posted in the Investor Relations section of its website
(www.arcabiopharma.com) and will also be available via webcast at:
http://wsw.com/webcast/gce/abio/.
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted
therapies for cardiovascular diseases. The Company's lead product
candidate, GencaroTM (bucindolol hydrochloride), is an
investigational, pharmacologically unique beta-blocker and mild
vasodilator being developed for atrial fibrillation. ARCA has
identified common genetic variations that it believes predict
individual patient response to Gencaro, giving it the potential to
be the first genetically-targeted atrial fibrillation prevention
treatment. ARCA has a collaboration with Medtronic, Inc. for
support of the GENETIC-AF trial. For more information please visit
www.arcabiopharma.com.
Safe Harbor Statement
This press release and the anticipated presentation contain
"forward-looking statements" for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
These statements include, but are not limited to, statements
regarding potential timing for patient enrollment in the GENETIC-AF
trial, the sufficiency of the Company’s capital to support its
operations, the potential for genetic variations to predict
individual patient response to Gencaro, Gencaro’s potential to
treat atrial fibrillation, the role of AF burden in diagnosis and
treatment of atrial fibrillation and the potential for Gencaro to
be the first genetically-targeted atrial fibrillation prevention
treatment. Such statements are based on management's current
expectations and involve risks and uncertainties. Actual results
and performance could differ materially from those projected in the
forward-looking statements as a result of many factors, including,
without limitation, the risks and uncertainties associated with:
the Company's financial resources and whether they will be
sufficient to meet the Company's business objectives and
operational requirements; results of earlier clinical trials may
not be confirmed in future trials, the protection and market
exclusivity provided by the Company’s intellectual property; risks
related to the drug discovery and the regulatory approval process;
and the impact of competitive products and technological changes.
These and other factors are identified and described in more detail
in ARCA’s filings with the SEC, including without limitation the
Company’s annual report on Form 10-K for the year ended December
31, 2013, and subsequent filings. The Company disclaims any intent
or obligation to update these forward-looking statements.
ARCA biopharma, Inc.Derek Cole,
720-940-2163derek.cole@arcabiopharma.com
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Feb 2024 to Mar 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Mar 2023 to Mar 2024